



Oracle Life Sciences

# **CancerMPact, EpiDatabase, and National Health and Wellness Survey Cloud Services**

## Service Descriptions and Metrics



Effective Date: 17-December-2024

## TABLE OF CONTENTS

|   |           |
|---|-----------|
| <b>Glossary</b>   | <b>4</b>  |
| Authorized User   | 4         |
| Co-Promote Partner  | 4         |
| Expanded Markets  | 4         |
| EU  | 4         |
| Indications   | 4         |
| Source Country Data   | 4         |
| Terms   | 4         |
| Therapeutic Area  | 4         |
| <b>METRICS</b>  | <b>5</b>  |
| Access Region   | 5         |
| Customer  | 5         |
| Hosted Named User   | 5         |
| <b>ORACLE LIFE SCIENCES CANCERMPACT (ALL TUMORS)</b>  | <b>6</b>  |
| Oracle Life Sciences CancerMPact (All Tumors) – [Country] – Patient Metrics - Customer  | 6         |
| Oracle Life Sciences CancerMPact (All Tumors) – [Country] – Treatment Architecture - Customer                                       | 7         |
| Oracle Life Sciences CancerMPact (All Tumors) – [Country] – Treatment Architecture Trends – Customer                                | 9         |
| Oracle Life Sciences CancerMPact (All Tumors) – US, EU and Japan Data – Cancer Landscape - Customer                                 | 10        |
| Oracle Life Sciences CancerMPact (All Tumors) – US, EU and Japan Data – Cancer Landscape for Emerging Companies – Hosted Named User | 11        |
| Oracle Life Sciences CancerMPact (All Tumors) – Future Trends and Insights – US, EU and Japan Data - Customer                       | 13        |
| <b>ORACLE LIFE SCIENCES CANCERMPACT (PER TUMOR)</b>   | <b>14</b> |
| Oracle Life Sciences CancerMPact (per Tumor) – [Country] – Patient Metrics - Customer   | 14        |
| Oracle Life Sciences CancerMPact (per Tumor) – [Country] – Treatment Architecture - Customer  | 16        |
| Oracle Life Sciences CancerMPact (per Tumor) – [Country] – Treatment Architecture Trends – Customer                                 | 17        |
| Oracle Life Sciences CancerMPact (per Tumor) – Future Trends and Insights – US, EU and Japan Data - Customer                        | 19        |
| <b>ORACLE LIFE SCIENCES CANCERMPACT JAPAN ACCESS (ALL TUMORS)</b>   | <b>21</b> |
| Oracle Life Sciences CancerMPact Japan Access (All Tumors) – [Country] – Patient Metrics - Customer                                 | 21        |
| Oracle Life Sciences CancerMPact Japan Access (All Tumors) – [Country] – Treatment Architecture - Customer                          | 22        |
| Oracle Life Sciences CancerMPact Japan Access (All Tumors) – [Country] – Treatment Architecture Trends – Customer                   | 24        |

|  |           |
|--|-----------|
| Oracle Life Sciences CancerMPact Japan Access (All Tumors) – US, EU and Japan Data – Cancer Landscape - Customer                                 | 25        |
| Oracle Life Sciences CancerMPact Japan Access (All Tumors) – US, EU and Japan Data – Cancer Landscape for Emerging Companies – Hosted Named User | 27        |
| Oracle Life Sciences CancerMPact Japan Access (All Tumors) – Future Trends and Insights – US, EU and Japan Data - Customer                       | 28        |
| <b>ORACLE LIFE SCIENCES CANCERMPACT JAPAN ACCESS (PER TUMOR)</b>   | <b>30</b> |
| Oracle Life Sciences CancerMPact Japan Access (per Tumor) – [Country] – Patient Metrics - Customer   | 30        |
| Oracle Life Sciences CancerMPact Japan Access (per Tumor) – [Country] – Treatment Architecture – Customer  | 31        |
| Oracle Life Sciences CancerMPact Japan Access (per Tumor) – [Country] – Treatment Architecture Trends – Customer                                 | 33        |
| Oracle Life Sciences CancerMPact Japan Access (per Tumor) – Future Trends and Insights – US, EU and Japan Data - Customer                        | 34        |
| <b>ORACLE LIFE SCIENCES EPI DATABASE (ALL INDICATIONS)</b>   | <b>36</b> |
| Oracle Life Sciences Epi Database (All Indications) – Access Region  | 36        |
| Oracle Life Sciences Epi Database (per Therapeutic Area) – Access Region   | 37        |
| Oracle Life Sciences Epi Database (per Indication) – Access Region   | 39        |
| <b>ORACLE LIFE SCIENCES NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)</b>   | <b>41</b> |
| Oracle Life Sciences NHWS – US & Europe Data - Customer  | 41        |

## GLOSSARY

### Authorized User

---

Authorized User means Client's employees whom Client has authorized to access the CancerMPact, Epi Database or National Health and Wellness Survey ("NHWS") through Client's Internet protocol/website.

### Co-Promote Partner

---

Co-Promote Partner: Another pharmaceutical company which is not a CancerMPact, Epi Database or NHWS subscriber and with whom the Client has agreed to share development and/or marketing efforts.

### Expanded Markets

---

Expanded Markets means Argentina, Brazil, Canada, India, Mexico, Republic of Korea, Russian Federation, Taiwan, Turkey.

### EU

---

EU means France, Germany, Italy, Spain, and the UK.

### Indications

---

Indications means a specific disease.

### Source Country Data

---

Source Country Data means the country where the data being provided has been sourced from.

### Terms

---

The following terms, as used in this document, Your order or the Agreement and whether or not capitalized, shall have the same meaning as the applicable defined term: "Agreement" and "Master Agreement"; "Customer", "Client", "Company", and "You"; "Program Documentation" and "Documentation"; "Ordering Document", "order", and "Order Form"; "Services Term" and "Services Period"; "Your Data", "Company Data", and "Your Content".

### Therapeutic Area

---

Therapeutic Area means a group of Indications with similar etiologies.

## METRICS

### Access Region

---

Access Region means a country or area of the world from which a client wishes to access the Oracle Life Sciences offering. A separate license is required for each Access Region, which comprises the following: Europe, United States, Japan, China, Rest of the World (ROW).

For the purposes of the Oracle Life Sciences Epi Database services, these services shall not be used or accessed from the Territory of Japan, unless a specific Japan access license has been granted.

### Customer

---

Customer means Your entity specified on Your order. The Oracle Life Sciences offering may not be used or accessed for the business operations of any third party, including but not limited to Your customers, partners or Your affiliates. For the purposes of this document, Customer and Client shall have the same meaning.

For the purposes of the Oracle Life Sciences CancerMPact services, Customer shall mean the entity this is entering into the ordering document and its majority-owned Subsidiaries, where a majority-owned Subsidiary refers to a separate and distinct legal entity that is more than 50% owned by You.

For the purposes of the Oracle Life Sciences CancerMPact services, these services shall not be used or accessed from the Territory of Japan, unless a specific Japan access license has been granted. For the purposes of Oracle Life Sciences CancerMPact Japan Access service, this service shall only be used and/or accessed from the Territory of Japan.

### Hosted Named User

---

Hosted Named User means an individual authorized by You to access the Oracle Life Sciences offering, regardless of whether the individual is actively accessing the offering at any given time during the Service Period.

## ORACLE LIFE SCIENCES CANCERMPACT (ALL TUMORS)

### Oracle Life Sciences CancerMPact (All Tumors) – [Country] – Patient Metrics - Customer

#### Part #:

| Part Number | Source Country Data (“Country”)           |
|-------------|---|
| B106048     | US Data                                   |
| B106050     | EU Data                                   |
| B106052     | Japan Data                                |
| B106054     | China Data                                |
| B106059     | Expanded Market – Argentina Data          |
| B106060     | Expanded Market – Brazil Data             |
| B106061     | Expanded Market – Canada Data             |
| B106062     | Expanded Market – India Data              |
| B106063     | Expanded Market – Mexico Data             |
| B106064     | Expanded Market – Republic of Korea Data  |
| B106065     | Expanded Market – Russian Federation Data |
| B106066     | Expanded Market – Taiwan Data             |
| B106067     | Expanded Market – Turkey Data             |
| B106068     | All Expanded Market Countries Data        |

#### Modules and Features

This Cloud Service provides cancer epidemiology and proprietary treatment data. Data is updated annually. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact (All Tumors) – Patient Metrics data for the specific country(s) as specified in Your order.

#### Prerequisites

None

#### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Access to the Source Country Data listed on Your order
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Access to all tumors is available
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

#### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud

Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle’s sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

**Support**

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle’s help desk is not authorized to assist with the performance of disease-related custom consulting activity.

**Training**

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

**Oracle Cloud Policies:**

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

**Oracle Life Sciences CancerMPact (All Tumors) – [Country] – Treatment Architecture - Customer**

---

**Part #:**

| <b>Part Number</b> | <b>Source Country Data (“Country”)</b> |
|--------------------|--|
| B106049            | US Data                                |
| B106051            | EU Data                                |
| B106053            | Japan Data                             |
| B106055            | China Data                             |

**Modules and Features**

This Cloud Service provides in-depth quantitative analysis of treatment patterns and oncology drug utilization. Data is updated annually. Authorized Users of this Cloud Service are authorized to access the:

- Treatment Architecture data for all tumors for the specific country(s) as specified in Your order.

## Prerequisites

None

## Usage Limits

This Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Access to the Source Country Data listed on Your order
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Access to all tumors is available
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

## Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to the Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.



## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences CancerMPact (All Tumors) – [Country] – Treatment Architecture Trends – Customer

---

### Part #:

| Part Number | Source Country Data (“Country”) |
|-------------|---------------------------------|
| B109508     | US Data                         |
| B109509     | EU Data                         |
| B109510     | Japan Data                      |
| B109511     | China Data                      |

### Modules and Features

This Cloud Service provides a comparative analysis of cancer treatment over the past seven years with data sourced from prior Treatment Architecture (TA) surveys. This Cloud Service takes current and past years’ treatment data, standardizes it, and links it to other data elements from CancerMPact, to allow for comparisons, visualizations and insights into how global oncology markets have evolved.

Users of this Cloud Service are authorized to access the following modules and features:

- Treatment Architecture Trends data for the specific country(s) as specified in Your order.

### Prerequisites

**Base Cloud Service:** For each Service listed below, the Base Cloud Service identified is a prerequisite for such Service.

- For B109508 - Oracle Life Sciences CancerMPact (All Tumors) – US Data – Treatment Architecture Trends
  - **Base Cloud Service:** Oracle Life Sciences CancerMPact (All Tumors) – US Data – Treatment Architecture (Part #: B106049)
- For B109509 - Oracle Life Sciences CancerMPact (All Tumors) – EU Data – Treatment Architecture Trends
  - **Base Cloud Service:** Oracle Life Sciences CancerMPact (All Tumors) – EU Data – Treatment Architecture (Part #: B106051)
- For B109510 - Oracle Life Sciences CancerMPact (All Tumors) – Japan Data – Treatment Architecture Trends
  - **Base Cloud Service:** Oracle Life Sciences CancerMPact (All Tumors) – Japan Data – Treatment Architecture (Part #: B106053)
- For B109511 - Oracle Life Sciences CancerMPact (All Tumors) – China Data – Treatment Architecture Trends
  - **Base Cloud Service:** Oracle Life Sciences CancerMPact (All Tumors) – China Data – Treatment Architecture (Part #: B106055)

## Usage Limits

- This Cloud Service is subject to the Usage Limits for the Base Cloud Service, unless otherwise specified in this section.

## **This Cloud Service cannot be activated if there is less than six (6) months remaining of the subscription for the Base Cloud Service. Customer Responsibilities**

The customer responsibilities for this Cloud Service are the same as for the Base Cloud Service.

## Support

Support for this Cloud Service is the same as for the Base Cloud Service.

## Training

Training for this Cloud Service is the same as for the Base Cloud Service.

## Oracle Cloud Policies

The Oracle Cloud Policies for this Cloud Service are the same as for the Base Cloud Service.

## **Oracle Life Sciences CancerMPact (All Tumors) – US, EU and Japan Data – Cancer Landscape - Customer**

---

### **Part #: B106057**

### **Modules and Features**

This Cloud Service provides an interactive analysis of the oncology trial landscape across all phases of development by drug, target, tumor, and company owner/developer. Data is updated weekly. Authorized Users of this Cloud Service are authorized to access the:

- OLS CMP (All Tumors) – US, EU and Japan Data – Cancer Landscape

### **Prerequisites**

None

### **Usage Limits**

This Cloud Service is subject to usage limits based upon:

- Data only sourced and available from the following countries: US, EU and Japan
- Only Authorized Users are allowed to access and use this Cloud Service
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### **Customer Responsibilities**

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf.

Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>

## Oracle Life Sciences CancerMPact (All Tumors) – US, EU and Japan Data – Cancer Landscape for Emerging Companies – Hosted Named User

---

### Part #: B106058

### Modules and Features

This Cloud Service provides an interactive analysis of the oncology trial landscape across all phases of development by drug, target, tumor, and company owner/developer. Data is updated weekly. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact (All Tumors) – US, EU and Japan Data – Cancer Landscape for Emerging Companies

### Prerequisites

None

## Usage Limits

This Cloud Service is subject to usage limits based upon:

- Data only sourced and available from the following countries: US, EU and Japan
- Only Authorized Users are allowed to access and use this Cloud Service
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

## Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancerpact\\_support\\_grp@oracle.com](mailto:cancerpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences CancerMPact (All Tumors) – Future Trends and Insights – US, EU and Japan Data - Customer

---

**Part #: B106056**

### Modules and Features

This Cloud Service provides analysis of the changing oncology competitive landscape with focus on late-stage competitor development. Data is updated quarterly. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact (All Tumors) – Future Trends and Insights – US, EU and Japan Data

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Data only sourced and available from the following countries: US, EU and Japan
- Only Authorized Users are allowed to access and use this Cloud Service
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Access to all tumors is available
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

### Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions.

Oracle’s help desk is not authorized to assist with the performance of disease-related custom consulting activity.

### Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

### Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## ORACLE LIFE SCIENCES CANCERMPACT (PER TUMOR)

### Oracle Life Sciences CancerMPact (per Tumor) – [Country] – Patient Metrics - Customer

Part #:

| Part Number | Source Country Data (“Country”)           |
|-------------|---|
| B106069     | US Data                                   |
| B106071     | EU Data                                   |
| B106073     | Japan Data                                |
| B106075     | China Data                                |
| B106078     | Expanded Market – Argentina Data          |
| B106079     | Expanded Market – Brazil Data             |
| B106080     | Expanded Market – Canada Data             |
| B106081     | Expanded Market – India Data              |
| B106082     | Expanded Market – Mexico Data             |
| B106083     | Expanded Market – Republic of Korea Data  |
| B106084     | Expanded Market – Russian Federation Data |
| B106085     | Expanded Market – Taiwan Data             |
| B106086     | Expanded Market – Turkey Data             |
| B106087     | All Expanded Market Countries Data        |

### Modules and Features

This Cloud Service provides cancer, epidemiology and proprietary treatment data. Data is updated annually. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact (per Tumor) – Patient Metrics data for the specific country(s) as specified in Your order.

### Prerequisites

None

## Usage Limits

This Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Access to the Source Country Data listed on Your order
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Allows access to the number of tumors as specified in Your order
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

## Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences CancerMPact (per Tumor) – [Country] – Treatment Architecture - Customer

---

### Part #:

| Part Number | Source Country Data (“Country”) |
|-------------|---------------------------------|
| B106070     | US Data                         |
| B106072     | EU Data                         |
| B106074     | Japan Data                      |
| B106076     | China Data                      |

### Modules and Features

This Cloud Service provides in-depth quantitative analysis of treatment patterns and oncology drug utilization. Data is updated annually. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact (per Tumor) – Treatment Architecture data for the specific country(s) as specified in Your order.

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Access to the Source Country Data listed on Your order
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Allows access to the number of tumors as specified in Your order
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle’s sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.



## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancerpact\\_support\\_grp@oracle.com](mailto:cancerpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences CancerMPact (per Tumor) – [Country] – Treatment Architecture Trends – Customer

---

### Part #:

| Part Number | Source Country Data ("Country") |
|-------------|---------------------------------|
| B109512     | US Data                         |
| B109513     | EU Data                         |
| B109514     | Japan Data                      |
| B109515     | China Data                      |

## Modules and Features

This Cloud Service provides a comparative analysis of cancer treatment over the past seven years with data sourced from prior Treatment Architecture (TA) surveys. This Cloud Service takes current and past years' treatment data, standardizes it, links it to other data elements from CancerMPact, to allow for comparisons, visualizations and insights into how global oncology markets have evolved.

Users of this Cloud Service are authorized to access the following modules and features:

- Treatment Architecture Trends data for the specific country(s) and tumor(s) as specified in Your order.

## Prerequisites

Base Cloud Service: For each Service listed below, the Base Cloud Service identified is a prerequisite for such Service.

- For B109512 - Oracle Life Sciences CancerMPact (per Tumor) – US Data – Treatment Architecture Trends
  - Base Cloud Service: Oracle Life Sciences CancerMPact (per Tumor) – US Data – Treatment Architecture (Part #: B106070)
- For B109513 - Oracle Life Sciences CancerMPact (per Tumor) – EU Data – Treatment Architecture Trends
  - Base Cloud Service: Oracle Life Sciences CancerMPact (per Tumor) – EU Data – Treatment Architecture (Part #: B106072)
- For B109514 - Oracle Life Sciences CancerMPact (per Tumor) – Japan Data – Treatment Architecture Trends
  - Base Cloud Service: Oracle Life Sciences CancerMPact (per Tumor) – Japan Data – Treatment Architecture (Part #: B106074)
- For B109515 - Oracle Life Sciences CancerMPact (per Tumor) – China Data – Treatment Architecture Trends
  - Base Cloud Service: Oracle Life Sciences CancerMPact (per Tumor) – China Data – Treatment Architecture (Part #: B106076)

## Usage Limits

- This Cloud Service is subject to the Usage Limits for the Base Cloud Service, unless otherwise specified in this section.
- This Cloud Service cannot be activated if there is less than six (6) months remaining of the subscription for the Base Cloud Service.

## Customer Responsibilities

The customer responsibilities for this Cloud Service are the same as for the Base Cloud Service.

## Support

Support for this Cloud Service is the same as for the Base Cloud Service.

## Training

Training for this Cloud Service is the same as for the Base Cloud Service.

## Oracle Cloud Policies

The Oracle Cloud Policies for this Cloud Service are the same as for the Base Cloud Service.

## Oracle Life Sciences CancerMPact (per Tumor) – Future Trends and Insights – US, EU and Japan Data - Customer

---

**Part #: B106077**

### Modules and Features

This Cloud Service provides analysis of the changing oncology competitive landscape with a focus on late-stage competitor development. Authorized Users this Cloud Service are authorized to access the:

- CancerMPact (per Tumor) – Future Trends and Insights – US, EU and Japan Data

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Data only sourced and available from the following countries: US, EU and Japan
- Only Authorized Users are allowed to access and use this Cloud Service
- Allows access to the number of tumors as specified in Your order
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

### Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpect\\_support\\_grp@oracle.com](mailto:cancermpect_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## ORACLE LIFE SCIENCES CANCERMPACT JAPAN ACCESS (ALL TUMORS)

### Oracle Life Sciences CancerMPact Japan Access (All Tumors) – [Country] – Patient Metrics - Customer

---

#### Part #:

| Part Number | Source Country Data (“Country”)           |
|-------------|---|
| B106088     | US Data                                   |
| B106090     | EU Data                                   |
| B106092     | Japan Data                                |
| B106094     | China Data                                |
| B106099     | Expanded Market – Argentina Data          |
| B106100     | Expanded Market – Brazil Data             |
| B106101     | Expanded Market – Canada Data             |
| B106102     | Expanded Market – India Data              |
| B106103     | Expanded Market – Mexico Data             |
| B106104     | Expanded Market – Republic of Korea Data  |
| B106105     | Expanded Market – Russian Federation Data |
| B106106     | Expanded Market – Taiwan Data             |
| B106107     | Expanded Market – Turkey Data             |
| B106108     | All Expanded Market Countries Data        |

#### Modules and Features

This Cloud Service provides cancer, epidemiology and proprietary treatment data. Data is updated annually. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact Japan Access (All Tumors) – Patient Metrics data for the specific country(s) as specified in Your order.

#### Prerequisites

None

#### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Access to the Source Country Data listed on Your order
- Data can only be used or accessed from regions or countries for which an access license has been granted
- Access to all tumors is available
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

#### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud

Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing the Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle’s sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

**Support**

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle’s help desk is not authorized to assist with the performance of disease-related custom consulting activity.

**Training**

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

**Oracle Cloud Policies**

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

**Oracle Life Sciences CancerMPact Japan Access (All Tumors) – [Country] – Treatment Architecture - Customer**

---

**Part #:**

| <b>Part Number</b> | <b>Source Country Data (“Country”)</b> |
|--------------------|--|
| B106089            | US Data                                |
| B106091            | EU Data                                |
| B106093            | Japan Data                             |
| B106095            | China Data                             |

## Modules and Features

This Cloud Service provides in-depth quantitative analysis of treatment patterns and oncology drug utilization. Data is updated annually. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact Japan Access (All Tumors) – Treatment Architecture data for the specific country(s) as specified in Your order.

## Prerequisites

None

## Usage Limits

The Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Access to the Source Country Data listed on Your order
- Data can only be used or accessed from regions or countries for which an access license has been granted
- Access to all tumors is available
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

## Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences CancerMPact Japan Access (All Tumors) – [Country] – Treatment Architecture Trends – Customer

---

### Part #:

| Part Number | Source Country Data (“Country”) |
|-------------|---------------------------------|
| B109516     | US Data                         |
| B109517     | EU Data                         |
| B109518     | Japan Data                      |
| B109519     | China Data                      |

## Modules and Features

This Cloud Service provides a comparative analysis of cancer treatment over the past seven years with data sourced from prior Treatment Architecture (TA) surveys. This Cloud Service takes current and past years’ treatment data, standardizes it, and links it to other data elements from CancerMPact, to allow for comparisons, visualizations and insights into how global oncology markets have evolved.

Users of this Cloud Service are authorized to access the following modules and features:

- Treatment Architecture Trends data for the specific country(s) as specified in Your order.

## Prerequisites

**Base Cloud Service:** For each Service listed below, the Base Cloud Service identified is a prerequisite for such Service.

- For B109516 - Oracle Life Sciences CancerMPact Japan Access (All Tumors) – US Data – Treatment Architecture Trends
  - **Base Cloud Service:** Oracle Life Sciences CancerMPact Japan Access (All Tumors) – US Data – Treatment Architecture (Part #: B106089)
- For B109517 - Oracle Life Sciences CancerMPact Japan Access (All Tumors) – EU Data – Treatment Architecture Trends
  - **Base Cloud Service:** Oracle Life Sciences CancerMPact Japan Access (All Tumors) – EU Data – Treatment Architecture (Part #: B106091)
- For B109518 - Oracle Life Sciences CancerMPact Japan Access (All Tumors) – Japan Data – Treatment Architecture Trends



- Base Cloud Service: Oracle Life Sciences CancerMPact Japan Access (All Tumors) – Japan Data – Treatment Architecture (Part #: B106093)
- For B109519 - Oracle Life Sciences CancerMPact Japan Access (All Tumors) – China Data – Treatment Architecture Trends
  - Base Cloud Service: Oracle Life Sciences CancerMPact Japan Access (All Tumors) – China Data – Treatment Architecture (Part #: B106095)

### Usage Limits

- This Cloud Service is subject to the Usage Limits for the Base Cloud Service, unless otherwise specified in this section.
- This Cloud Service cannot be activated if there is less than six (6) months remaining of the subscription for the Base Cloud Service.

### Customer Responsibilities

The customer responsibilities for this Cloud Service are the same as for the Base Cloud Service.

### Support

Support for this Cloud Service is the same as for the Base Cloud Service.

### Training

Training for this Cloud Service is the same as for the Base Cloud Service.

### Oracle Cloud Policies

The Oracle Cloud Policies for this Cloud Service are the same as for the Base Cloud Service.

## Oracle Life Sciences CancerMPact Japan Access (All Tumors) – US, EU and Japan Data – Cancer Landscape - Customer

---

### Part #: B106097

### Modules and Features

This Cloud Service provides interactive analytics of the oncology trial landscape across all phases of development by drug, target, tumor and company owner/developer. Data is updated weekly. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact Japan Access (All Tumors) – US, EU and Japan Data – Cancer Landscape

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Data only sourced and available from the following countries: US, EU and Japan
- Only Authorized Users are allowed to access and use this Cloud Service

- Data can only be used or accessed from regions or countries for which an access license has been granted
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### **Customer Responsibilities**

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

### **Support**

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

### **Training**

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop the Cloud Service. In-person training may be subject to additional fees.

### **Oracle Cloud Policies**

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences CancerMPact Japan Access (All Tumors) – US, EU and Japan Data – Cancer Landscape for Emerging Companies – Hosted Named User

---

**Part #: B106098**

### Modules and Features

This Cloud Service provides interactive analytics of the oncology trial landscape across all phases of development by drug, target, tumor and company owner/developer. Data is updated weekly. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact Japan Access (All Tumors) – US, EU and Japan Data – Cancer Landscape for Emerging Companies

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Data only sourced and available from the following countries: US, EU and Japan
- Only Authorized Users are allowed to access and use this Cloud Service
- Data can only be used or accessed from regions or countries for which an access license has been granted
- Use of the Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

### Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions.

Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences CancerMPact Japan Access (All Tumors) – Future Trends and Insights – US, EU and Japan Data - Customer

---

**Part #: B106096**

### Modules and Features

This Cloud Service provides analysis of the changing oncology competitive landscape with a focus on late-stage competitor development. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact Japan Access (All Tumors) – Future Trends and Insights – US, EU and Japan Data

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Data only sourced and available from the following countries: US, EU and Japan
- Only Authorized Users are allowed to access and use this Cloud Service
- Data can only be used or accessed from regions or countries for which an access license has been granted
- Access to all tumors is available
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## ORACLE LIFE SCIENCES CANCERMPACT JAPAN ACCESS (PER TUMOR)

### Oracle Life Sciences CancerMPact Japan Access (per Tumor) – [Country] – Patient Metrics - Customer

---

#### Part #:

| Part Number | Source Country Data (“Country”)           |
|-------------|---|
| B106109     | US Data                                   |
| B106111     | EU Data                                   |
| B106113     | Japan Data                                |
| B106115     | China Data                                |
| B106118     | Expanded Market – Argentina Data          |
| B106119     | Expanded Market – Brazil Data             |
| B106120     | Expanded Market – Canada Data             |
| B106121     | Expanded Market – India Data              |
| B106122     | Expanded Market – Mexico Data             |
| B106123     | Expanded Market – Republic of Korea Data  |
| B106124     | Expanded Market – Russian Federation Data |
| B106125     | Expanded Market – Taiwan Data             |
| B106126     | Expanded Market – Turkey Data             |
| B106127     | All Expanded Market Countries Data        |

#### Modules and Features

This Cloud Service provides cancer, epidemiology and proprietary treatment data. Data is updated annually. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact Japan Access (per Tumor) – Patient Metrics data for the specific country(s) as specified in Your order.

#### Prerequisites

None

#### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Access to the Source Country Data listed on Your order
- Data can only be used or accessed from regions or countries for which an access license has been granted
- Allows access to the number of tumors as specified in Your order
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

#### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud

Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle’s sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

**Support**

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle’s help desk is not authorized to assist with the performance of disease-related custom consulting activity.

**Training**

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

**Oracle Cloud Policies**

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

**Oracle Life Sciences CancerMPact Japan Access (per Tumor) – [Country] – Treatment Architecture – Customer**

---

**Part #:**

| <b>Part Number</b> | <b>Source Country Data (“Country”)</b> |
|--------------------|--|
| B106110            | US Data                                |
| B106112            | EU Data                                |
| B106114            | Japan Data                             |
| B106116            | China Data                             |

## Modules and Features

This Cloud Service provide in-depth quantitative analysis of treatment patterns and oncology drug utilization. Data is updated annually. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact Japan Access (per Tumor) – Treatment Architecture data for the specific country(s) as specified in Your order.

## Prerequisites

None

## Usage Limits

This Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Access to the Source Country Data listed on Your order
- Data can only be used or accessed from regions or countries for which an access license has been granted
- Allows access to the number of tumors as specified in Your order
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

## Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.



## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences CancerMPact Japan Access (per Tumor) – [Country] – Treatment Architecture Trends – Customer

---

### Part #:

| Part Number | Source Country Data (“Country”) |
|-------------|---------------------------------|
| B109520     | US Data                         |
| B109521     | EU Data                         |
| B109522     | Japan Data                      |
| B109523     | China Data                      |

## Modules and Features

This Cloud Service provides a comparative analysis of cancer treatment over the past seven years with data sourced from prior Treatment Architecture (TA) surveys. This Cloud Service takes current and past years’ treatment data, standardizes it, and links it to other data elements from CancerMPact, to allow for comparisons, visualizations and insights into how global oncology markets have evolved.

Users of this Cloud Service are authorized to access the following modules and features:

- Treatment Architecture Trends data for the specific country(s) and tumor(s) as specified in Your order.

## Prerequisites

Base Cloud Service: For each Service listed below, the Base Cloud Service identified is a prerequisite for such Service.

- For B109520 - Oracle Life Sciences CancerMPact Japan Access (per Tumor) – US Data – Treatment Architecture Trends
  - Base Cloud Service: Oracle Life Sciences CancerMPact Japan Access (per Tumor) – US Data – Treatment Architecture (Part #: B106110)
- For B109521 - Oracle Life Sciences CancerMPact Japan Access (per Tumor) – EU Data – Treatment Architecture Trends
  - Base Cloud Service: Oracle Life Sciences CancerMPact Japan Access (per Tumor) – EU Data – Treatment Architecture (Part #: B106112)
- For B109522 - Oracle Life Sciences CancerMPact Japan Access (per Tumor) – Japan Data – Treatment Architecture Trends

- Base Cloud Service: Oracle Life Sciences CancerMPact Japan Access (per Tumor) – Japan Data – Treatment Architecture (Part #: B106114)
- For B109523 - Oracle Life Sciences CancerMPact Japan Access (per Tumor) – China Data – Treatment Architecture Trends
  - Base Cloud Service: Oracle Life Sciences CancerMPact Japan Access (per Tumor) – China Data – Treatment Architecture (Part #: B106116)

### Usage Limits

- This Cloud Service is subject to the Usage Limits for the Base Cloud Service, unless otherwise specified in this section.
- This Cloud Service cannot be activated if there is less than six (6) months remaining of the subscription for the Base Cloud Service.

### Customer Responsibilities

The customer responsibilities for this Cloud Service are the same as for the Base Cloud Service.

### Support

Support for this Cloud Service is the same as for the Base Cloud Service.

### Training

Training for this Cloud Service is the same as for the Base Cloud Service.

### Oracle Cloud Policies

The Oracle Cloud Policies for this Cloud Service are the same as for the Base Cloud Service.

## Oracle Life Sciences CancerMPact Japan Access (per Tumor) – Future Trends and Insights – US, EU and Japan Data - Customer

---

### Part #: B106117

### Modules and Features

This Cloud Service provides analysis of the changing oncology competitive landscape with a focus on late-stage competitor development. Authorized Users of this Cloud Service are authorized to access the:

- CancerMPact Japan Access (per Tumor) – Future Trends and Insights – US, EU and Japan Data

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Data only sourced and available from the following countries: US, EU and Japan
- Only Authorized Users are allowed to access and use this Cloud Service

- Allows access to the number of tumors as specified in Your order
- Data can only be used or accessed from regions or countries for which an access license has been granted
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### **Customer Responsibilities**

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

### **Support**

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [cancermpact\\_support\\_grp@oracle.com](mailto:cancermpact_support_grp@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

### **Training**

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

### **Oracle Cloud Policies**

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## ORACLE LIFE SCIENCES EPI DATABASE (ALL INDICATIONS)

### Oracle Life Sciences Epi Database (All Indications) – Access Region

#### Part #:

| Part Number | Access Region                             | Included Countries  |
|-------------|---|---|
| B106128     | Core7 Data                                | United States, Japan, France, Germany, Italy, Spain and the United Kingdom. |
| B106129     | BRIC Data                                 | Brazil, Russian, India, and China   |
| B106130     | Emerging Markets Data                     | Mexico and Turkey.  |
| B106131     | China Data                                | China   |
| B106132     | Brazil Data                               | Brazil  |
| B106133     | US Data                                   | US  |
| B106134     | UK, France, Germany, Italy and Spain Data | UK, France, Germany, Italy and Spain  |
| B106135     | Japan Data                                | Japan   |

#### Modules and Features

This Cloud Service provides epidemiology data segmented by country, Indication, year, gender, race, and age. Authorized Users of this Cloud Service are authorized to access the:

- Epi Database (All Indications) data for the specific country(s) as specified in Your order.

#### Prerequisites

None

#### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Access to the Access Region as listed on Your order
- Only Authorized Users are allowed to access and use this Cloud Service
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

#### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle’s sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle’s help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

## Oracle Life Sciences Epi Database (per Therapeutic Area) – Access Region

---

### Part #:

| Part Number | Access Region                             | Included Countries  |
|-------------|---|---|
| B106136     | Core7 Data                                | United States, Japan, France, Germany, Italy, Spain and the United Kingdom. |
| B106137     | BRIC Data                                 | Brazil, Russian, India, and China.  |
| B106138     | Emerging Markets Data                     | Mexico and Turkey.  |
| B106139     | China Data                                | China   |
| B106140     | Brazil Data                               | Brazil  |
| B106141     | US Data                                   | US  |
| B106142     | UK, France, Germany, Italy and Spain Data | UK, France, Germany, Italy and Spain  |
| B106143     | Japan Data                                | Japan   |

## Modules and Features

This Cloud Service provides epidemiology data segmented by country, Indication, year, gender, race, and age. Authorized Users of this Cloud Service are authorized to access the:

- Epi Database (per Therapeutic Area) data for the specific country(s) as specified in Your order.

## Prerequisites

None

## Usage Limits

This Cloud Service is subject to usage limits based upon:

- Access to the Access Region as listed on Your order
- Allows access to the quantity of therapeutic areas as specified in Your order
- Only Authorized Users are allowed to access and use this Cloud Service.
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

## Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-promote partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use

this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

### Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle’s latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.

### Oracle Life Sciences Epi Database (per Indication) – Access Region

---

#### Part #:

| Part Number | Access Region                             | Minimum Number of Diseases  |
|-------------|---|---|
| B106144     | Core7 Data                                | United States, Japan, France, Germany, Italy, Spain and the United Kingdom. |
| B106145     | BRIC Data                                 | Brazil, Russian, India, and China.  |
| B106146     | Emerging Markets Data                     | Mexico and Turkey.  |
| B106147     | China Data                                | China   |
| B106148     | Brazil Data                               | Brazil  |
| B106149     | US Data                                   | US  |
| B106150     | UK, France, Germany, Italy and Spain Data | UK, France, Germany, Italy and Spain  |
| B106151     | Japan Data                                | Japan   |

### Modules and Features

This Cloud Service provides epidemiology data segmented by country, Indication, year, gender, race, and age. Authorized Users of this Cloud Service are authorized to access the:

- Epi Database (per Indication) data for the specific country(s) as specified in Your order.

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Access to the Access Region as listed on Your order
- Allows access to the quantity of Indications as specified in Your order
- Only Authorized Users are allowed to access and use this Cloud Service.
- Data cannot be used or accessed from the Territory of Japan, unless a Japan access license has been granted
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

## Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by video conference, telephone or email as needed to answer Your questions about report content. Requests for support can be sent to [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com). Custom runs of data or other detailed service requests can be provided for an additional fee.

Oracle will maintain a technical help desk (available at [lsappstechsupport\\_ww@oracle.com](mailto:lsappstechsupport_ww@oracle.com)) capable of providing assistance regarding connection to the host and operating instructions for access to, and use of, this Cloud Service. Such assistance shall be available Monday through Friday (excluding holidays), from 9:00 a.m. until 4:00 p.m. Central Time (CT), subject to planned or uncontrolled interruptions. Oracle's help desk is not authorized to assist with the performance of disease-related custom consulting activity.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to access and use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.



# ORACLE LIFE SCIENCES NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)

## Oracle Life Sciences NHWS – US & Europe Data - Customer

---

**Part #: B106152**

### Modules and Features

This Cloud Service is a survey of the general population that collects detailed information about patients with specific conditions and how they treat those conditions. It is a syndicated database of over 200K validated patient reported outcomes data across 200+ diseases / conditions from 12 countries. Includes cross-sectional data spanning 2 million patients and 20+ years. US Data is updated annually and European Data is updated at least every other year.

NHWS Europe data collected for UK, Germany, Italy, Spain and France.

Authorized Users of this Cloud Service are authorized to access the:

- NHWS – US & Europe Data.

### Prerequisites

None

### Usage Limits

This Cloud Service is subject to usage limits based upon:

- Only Authorized Users are allowed to access and use this Cloud Service
- Use of this Cloud Service by anyone but You is not allowed except as otherwise specified in these Service Descriptions or Your Order.

### Customer Responsibilities

Upon written permission from Oracle, You may disseminate downloaded information to a third party in either electronic or hard copy format. You agree to assume sole responsibility for use of this Cloud Service and reports by Your employees, contractors, and all other third parties acting on Your behalf. Should You not obtain the proper authorization for use by a third party, Oracle may immediately terminate Your access to this Cloud Service.

Sharing this Cloud Service with an additional company site is not allowed. Additional company site licenses are required to be purchased from Oracle for additional company sites to access this Cloud Service. Upon request for the additional company site license and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

Sharing this Cloud Service with a Co-Promote Partner is not allowed. Co-Promote Partners are required to purchase their own applicable license from Oracle to access this Cloud Service. Upon request of the Co-Promote Partner and at Oracle's sole discretion, these licenses may be prorated to co-terminate with the term of Your Order.

## Support

Oracle will be available by telephone or email ([NHWS\\_support\\_grp@oracle.com](mailto:NHWS_support_grp@oracle.com)) as needed to answer Your questions about this Cloud Service. Custom runs of data or other detailed service requests can be provided for an additional fee.

## Training

Upon request and at a mutually agreed upon time, Oracle shall provide You with introductory training via web or phone-based conferencing. Such introductory training shall address how to use this Cloud Service, and an explanation of the methodologies used to develop this Cloud Service. In-person training may be subject to additional fees.

## Oracle Cloud Policies

- **Privacy.** Email addresses of subscribers to this Cloud Service will be used by Oracle to keep You informed of Oracle's latest products and services or other promotional purpose. Users may opt out at any time after registration: <https://www.cernerenviza.com/privacy-notice>.